These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 37468280)

  • 21. A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor.
    Hirokawa Y; Tikoo A; Huynh J; Utermark T; Hanemann CO; Giovannini M; Xiao GH; Testa JR; Wood J; Maruta H
    Cancer J; 2004; 10(1):20-6. PubMed ID: 15000491
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neurofibromatosis type 2.
    Uppal S; Coatesworth AP
    Int J Clin Pract; 2003 Oct; 57(8):698-703. PubMed ID: 14627181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neurofibromatosis-related tumors: emerging biology and therapies.
    Karajannis MA; Ferner RE
    Curr Opin Pediatr; 2015 Feb; 27(1):26-33. PubMed ID: 25490687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genomics, Epigenetics, and Hearing Loss in Neurofibromatosis Type 2.
    Dinh CT; Nisenbaum E; Chyou D; Misztal C; Yan D; Mittal R; Young J; Tekin M; Telischi F; Fernandez-Valle C; Liu XZ
    Otol Neurotol; 2020 Jun; 41(5):e529-e537. PubMed ID: 32150022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Type 2 neurofibromatosis: intergenerational differences in genetic and clinical expression].
    Drouet A; Le Moigne F; Salamé D; Quesnel L; Motolese C; des Portes V; Guilloton L; Pinson S
    Arch Pediatr; 2014 Nov; 21(11):1233-40. PubMed ID: 25439059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Neurofibromatosis type 2 (NF2)].
    Araki N; Takeshima H; Saya H
    Gan To Kagaku Ryoho; 1997 Sep; 24(11):1427-31. PubMed ID: 9309136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neurofibromatosis type 2.
    Evans DG; Sainio M; Baser ME
    J Med Genet; 2000 Dec; 37(12):897-904. PubMed ID: 11106352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Somatic Mosaicism of NF2 Gene Mutation with Constitutional NF1 Gene Mutation in Neurofibromatosis Type 2: a Case Report.
    Yoo SJ; Hwang YS
    Clin Lab; 2020 Nov; 66(11):. PubMed ID: 33180429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cellular prion protein (PrP
    Provenzano L; Ryan Y; Hilton DA; Lyons-Rimmer J; Dave F; Maze EA; Adams CL; Rigby-Jones R; Ammoun S; Hanemann CO
    Oncogene; 2017 Nov; 36(44):6132-6142. PubMed ID: 28692055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional analysis of neurofibromatosis 2 (NF2) missense mutations.
    Gutmann DH; Hirbe AC; Haipek CA
    Hum Mol Genet; 2001 Jul; 10(14):1519-29. PubMed ID: 11448944
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel neurofibromatosis type 2 mutation presenting with status epilepticus.
    DiFrancesco JC; Sestini R; Cossu F; Bolognesi M; Sala E; Mariani S; Saracchi E; Papi L; Ferrarese C
    Epileptic Disord; 2014 Mar; 16(1):132-7. PubMed ID: 24667735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Neurofibromatosis type 2 (central neurofibromatosis or bilateral acoustic neuromas, vestibular schwannomas): from phenotype to gene].
    Sabol Z; Kipke-Sabol L; Miklić P; Hajnsek-Propadalo S; Sabol F
    Lijec Vjesn; 2006; 128(9-10):309-16. PubMed ID: 17128670
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Magic but treatable? Tumours due to loss of merlin.
    Hanemann CO
    Brain; 2008 Mar; 131(Pt 3):606-15. PubMed ID: 17940085
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis.
    Smith MJ; Bowers NL; Bulman M; Gokhale C; Wallace AJ; King AT; Lloyd SK; Rutherford SA; Hammerbeck-Ward CL; Freeman SR; Evans DG
    Neurology; 2017 Jan; 88(1):87-92. PubMed ID: 27856782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction and evaluation of deleterious and disease causing non-synonymous SNPs (nsSNPs) in human NF2 gene responsible for neurofibromatosis type 2 (NF2).
    Havranek B; Islam SM
    J Biomol Struct Dyn; 2021 Nov; 39(18):7044-7055. PubMed ID: 32787631
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of drug treatments for neurofibromatosis type 2-associated vestibular schwannoma.
    Blakeley J
    Curr Opin Otolaryngol Head Neck Surg; 2012 Oct; 20(5):372-9. PubMed ID: 22931905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas.
    Kluwe L; Mautner V; Heinrich B; Dezube R; Jacoby LB; Friedrich RE; MacCollin M
    J Med Genet; 2003 Feb; 40(2):109-14. PubMed ID: 12566519
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of SIRT2 in merlin/NF2-mutant Schwann cells triggers necrosis.
    Petrilli A; Bott M; Fernández-Valle C
    Oncotarget; 2013 Dec; 4(12):2354-65. PubMed ID: 24259290
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2.
    Blakeley JO; Evans DG; Adler J; Brackmann D; Chen R; Ferner RE; Hanemann CO; Harris G; Huson SM; Jacob A; Kalamarides M; Karajannis MA; Korf BR; Mautner VF; McClatchey AI; Miao H; Plotkin SR; Slattery W; Stemmer-Rachamimov AO; Welling DB; Wen PY; Widemann B; Hunter-Schaedle K; Giovannini M
    Am J Med Genet A; 2012 Jan; 158A(1):24-41. PubMed ID: 22140088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of NF2 haploinsufficiency in NF2-associated polyneuropathy.
    Hanemann CO; Diebold R; Kaufmann D
    Brain Pathol; 2007 Oct; 17(4):371-6. PubMed ID: 17655741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.